Login / Signup

The HROC-Xenobank-A High Quality Assured PDX Biobank of >100 Individual Colorectal Cancer Models.

Stephanie MatschosFlorian BürtinSaid KdimatiMandy RadefeldtSusann KrakeFriedrich PrallNadja EngelMathias KrohnBianca MicheelMichael KreutzerChristina Susanne MullinsMichael Linnebacher
Published in: Cancers (2021)
Based on our research group's large biobank of colorectal cancers (CRC), we here describe the ongoing activity of establishing a high quality assured PDX biobank for more than 100 individual CRC cases. This includes sufficient numbers of vitally frozen (n > 30 aliquots) and snap frozen (n > 5) backups, "ready to use". Additionally, PDX tumor pieces were paraffin embedded. At the current time, we have completed 125 cases. This resource allows histopathological examinations, molecular characterizations, and gene expression analysis. Due to its size, different issues of interest can be addressed. Most importantly, the application of low-passage, cryopreserved, and well-characterized PDX for in vivo studies guarantees the reliability of results due to the largely preserved tumor microenvironment. All cases described were molecularly subtyped and genetic identity, in comparison to the original tumor tissue, was confirmed by fingerprint analysis. The latter excludes ambiguity errors between the PDX and the original patient tumor. A cancer hot spot mutation analysis was performed for n = 113 of the 125 cases entities. All relevant CRC molecular subtypes identified so far are represented in the Hansestadt Rostock CRC (HROC)-Xenobank. Notably, all models are available for cooperative research approaches.
Keyphrases
  • genome wide
  • papillary thyroid
  • bone marrow
  • patient safety
  • genome wide identification
  • mesenchymal stem cells
  • single molecule
  • transcription factor
  • quality control
  • lymph node metastasis